公开(公告)号：US20160228496A1

公开(公告)日：2016-08-11

申请号：US14208266

申请日：2014-03-13

Applicant: AbbVie Inc.

Inventor： Daniel E. Cohen ,  Kenneth B. Idler ,  Jeffrey F. Waring ,  Emily O. Dumas ,  Sandeep Dutta

IPC: A61K38/12 ,  A61K38/05 ,  C12Q1/68 ,  A61K31/513

CPC classification number: A61K38/12 ,  A61K31/513 ,  A61K31/7056 ,  A61K38/21 ,  A61K45/06 ,  C12Q1/6883 ,  C12Q1/707 ,  C12Q2600/154 ,  A61K2300/00

Abstract: The present invention features therapies for the treatment of HCV comprising direct-acting antiviral agents. Preferably, the treatment is administered to an HCV-infected patient who has been tested to determine methylation status of a CpG island within a promoter region of the IL28B gene. In one aspect, the therapies comprise administering one or more direct acting antiviral agents and, optionally ribavirin, to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2, therapeutic agent 3, an inhibitor of cytochrome P450 (e.g., ritonavir), and/or ribavirin.

公开(公告)号：US20160237491A1

公开(公告)日：2016-08-18

申请号：US14536894

申请日：2014-11-10

Applicant: AbbVie Inc.

Inventor： Daniel E. Cohen ,  Kenneth B. Idler ,  Jeffrey F. Waring ,  Emily O. Dumas ,  Sandeep Dutta

IPC: C12Q1/68 ,  A61K38/05 ,  A61K31/7056 ,  A61K31/427 ,  A61K38/12 ,  A61K31/513

CPC classification number: C12Q1/6883 ,  A61K31/402 ,  A61K31/427 ,  A61K31/497 ,  A61K31/513 ,  A61K31/7056 ,  A61K38/05 ,  A61K38/12 ,  C12Q2600/106 ,  C12Q2600/154

Abstract: The present invention features therapies for the treatment of HCV comprising direct-acting antiviral agents. Preferably, the treatment is administered to an HCV-infected patient who has been tested to determine methylation status of a CpG island within a promoter region of the IL28B gene. In one aspect, the therapies comprise administering one or more direct acting antiviral agents and, optionally ribavirin, to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2, therapeutic agent 3, an inhibitor of cytochrome P450 (e.g., ritonavir), and/or ribavirin.

Abstract translation: 本发明的特征在于治疗包含直接作用的抗病毒剂的HCV的治疗。 优选地，将治疗施用于已经被测试以确定IL28B基因的启动子区域内的CpG岛的甲基化状态的HCV感染的患者。 在一个方面，治疗方法包括向具有HCV感染的受试者施用一种或多种直接作用的抗病毒剂和任选的利巴韦林。 例如，治疗包括向受试者施用有效量的治疗剂1，治疗剂2，治疗剂3，细胞色素P450抑制剂（例如利托那韦）和/或利巴韦林。

公开(公告)号：US20160333404A1

公开(公告)日：2016-11-17

申请号：US14557524

申请日：2014-12-02

Applicant: AbbVie Inc.

Inventor： Barry M. Bernstein ,  Isabelle A. Gaultier ,  Daniel E. Cohen ,  Jeffrey F. Waring ,  Stephen J. Abel ,  Emily O. Dumas

IPC: C12Q1/68 ,  A61K31/497 ,  A61K31/513 ,  A61K31/7056

CPC classification number: A61K31/513 ,  A61K31/4025 ,  A61K31/427 ,  A61K31/497 ,  A61K31/7056 ,  A61K38/212 ,  A61K45/06 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/178 ,  A61K2300/00

Abstract: The present invention features therapies for the treatment of HCV comprising direct-acting antiviral agents. Preferably, the treatment is administered to an HCV-infected patient who has been tested to determine expression levels of microRNAs such as miR-122 or miR-21. In one aspect, the therapies comprise administering one or more direct acting antiviral agents and, optionally ribavirin, to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2, an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.

Abstract translation: 本发明的特征在于治疗包含直接作用的抗病毒剂的HCV的治疗。 优选地，将治疗施用于经过测试以确定微小RNA如miR-122或miR-21的表达水平的HCV感染患者。 在一个方面，治疗方法包括向具有HCV感染的受试者施用一种或多种直接作用的抗病毒剂和任选的利巴韦林。 例如，治疗包括向受试者施用有效量的治疗剂1，治疗剂2，细胞色素P450的抑制剂（例如利托那韦）和利巴韦林。

公开(公告)号：US20130317056A1

公开(公告)日：2013-11-28

申请号：US13826532

申请日：2013-03-14

Applicant: ABBVIE INC.

Inventor： George M. Haig ,  Jeffrey F. Waring ,  Chih-Hung Lee ,  Deli Wang

IPC: C12Q1/68

CPC classification number: C12Q1/6883 ,  A61K31/439 ,  A61K31/444 ,  A61K31/4748 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N2800/302

Abstract: This application is directed to a-neuronal nicotinic receptor agonists selective for α7-subtype that are useful for improving cognition impairment in patients having schizophrenia, a schizophreniform disorder or a related schizophrenia spectrum psychotic disorder. Compounds and compositions containing such compounds, and methods of using such compound and compositions are described herein.

Abstract translation: 该应用涉及对α7亚型选择性的α-神经元烟碱受体激动剂，其可用于改善患有精神分裂症，精神分裂症或相关精神分裂症光谱精神病的患者的认知障碍。 包含这些化合物的化合物和组合物以及使用这种化合物和组合物的方法在本文中描述。